Page 47 - Pharma News Letter Vol1 Issue2 - Converted By Dr. Ahmed Rashed

Research Publications

Pharmacotherapy

First published: 18 May 2023

Effect of cilostazol on preventing paclitaxel-induced
neuropathy in patients with breast cancer: A randomized

controlled trial

Esraa A. Haroun , Noha O. Mansour , Ahmed evaluated through common terminology criteria
1
1
Eltantawy , Mohamed E. E.Shams 1 for adverse event (NCI-CTCAE) version 4.
2
1 Clinical Pharmacy and Pharmacy Practice Secondary endpoints included assessment of the
Department, Faculty of Pharmacy, Mansoura patient’s QoL by the Functional Assessment of
University, Mansoura, Egypt. Cancer Therapy/Gynecologic Oncology Group-
Neurotoxicity (FACT-GOG-NTx) subscale.
2 Medical Oncology Unit, Oncology Center, Exploratory outcome measures included
Mansoura University, Mansoura, Egypt. changes in serum levels of biomarkers namely
Abstract nerve growth factor (NGF), and neurofilament

Study Objective: Paclitaxel-induced peripheral light chain (NfL).
neuropathy is a significant clinical problem Main Results: The incidence of grade 2 and
can markedly deteriorate patient’s quality of 3 peripheral neuropathies were significantly
life (QoL). Preclinical evidence exists about lower in the cilostazol group (40%) compared
the preventive capacity of cilostazol against to the control group (86.7%) (p < 0.001). The
peripheral neuropathy. However, this hypothesis incidence of clinically significant worsening
has not yet been clinically investigated. This in neuropathy-related QoL was higher in
proof-of-concept study evaluated the effect control group compared to the cilostazol group
of cilostazol on the incidence of paclitaxel- (p = 0.001). A higher percent increase from
induced peripheral neuropathy in patients with baseline in serum NGF was observed in the
non-metastatic breast cancer. cilostazol group (p = 0.043). The circulating

Design: This is a parallel randomized placebo- levels of NfL deemed comparable between the
two arms at the end of the study (p = 0.593).
controlled trial.
Conclusion: Adjunctive use of cilostazol is as
Setting: The Oncology Center at Mansoura a novel option that might reduce the incidence
University, Egypt. of paclitaxel-induced peripheral neuropathy and
Patients: Patients with breast cancer scheduled improve the patients’ QoL. Future larger clinical
to receive paclitaxel 175 mg/m2 biweekly. trials are warranted to confirm these findings.
Interventions: Patients were randomized to https://doi.org/10.1002/phar.2830
either cilostazol group who received cilostazol
tablets 100 mg BID, or to control group who
received placebo instead.
Measurements: The primary endpoint was
the incidence of paclitaxel-induced neuropathy

Vol. 1 - Issue 2 47